EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

T-lymphoblastic leukemia/lymphoma: a comprehensive review of pathology, molecular features, and differential diagnosis

David Danielson, Ian T Lagerstrom, Max Rogers, Kyle Simon, Nadine S Aguilera, Aaron Auerbach

Journal of Pathology and Translational Medicine · 15.09.2026 · 60 (5) · 502-515

DOI: 10.4132/jptm.2026.08.01 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pathology and Translational Medicine, erschienen am 15.09.2026. Verfasst von David Danielson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Walter Reed National Military Medical Center, Bethesda, MD, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

T-lymphoblastic leukemia/lymphoma (T-ALL/LBL) is an aggressive neoplasm of immature T-lymphoid precursors that is classified as T-cell acute lymphoblastic leukemia when the primary site of involvement is the bone marrow and peripheral blood and as T-cell lymphoblastic lymphoma when it presents as a solid mass, most commonly in the anterior mediastinum. The neoplastic cells are defined by expression of T-lineage antigens (cytoplasmic or surface CD3) together with one or more markers of immaturity (terminal deoxynucleotidyl transferase, CD1a, CD34, CD99, or CD117) and must not fulfill criteria for early T-cell precursor acute lymphoblastic leukemia (ALL). This entity shows a marked male predominance (male:female ≈ 2:1) and predominantly affects children, adolescents, and young adults, accounting for approximately 15% of childhood ALL and 20%–25% of adult ALL cases. Pathologic diagnosis increasingly relies on recurrent molecular alterations such as activating NOTCH1 mutations (>60% of cases), transcription factor rearrangements, and cell-cycle regulator inactivation. Although intensive multiagent chemotherapy regimens have substantially improved outcomes, particularly in pediatric patients, adults and high-risk molecular subgroups continue to experience inferior survival. This review provides a practical, pathology-oriented update on the epidemiology, pathogenesis, diagnostic criteria, differential diagnosis, prognostic factors, and current treatment approaches for T-ALL/LBL.

Schlagwörter

Stichwörter der Autor:innen

Diagnosis, differentialImmunophenotypingLeukemia, T-cellPathology, molecularReview

Autor:innen und Institutionen

  • Walter Reed National Military Medical Center, Bethesda, MD, USA.
  • Walter Reed National Military Medical Center, Bethesda, MD, USA. lagerstromi@upmc.edu.
  • University of Virginia Health System, Charlottesville, VA, USA.
  • Joint Pathology Center, Silver Spring, MD, USA.

Zitieren

APA

Danielson, D., Lagerstrom, I. T., Rogers, M., Simon, K., Aguilera, N. S., & Auerbach, A. (2026). T-lymphoblastic leukemia/lymphoma: a comprehensive review of pathology, molecular features, and differential diagnosis. Journal of Pathology and Translational Medicine, 60(5), 502-515. https://doi.org/10.4132/jptm.2026.08.01

Vancouver

Danielson D, Lagerstrom IT, Rogers M, Simon K, Aguilera NS, Auerbach A. T-lymphoblastic leukemia/lymphoma: a comprehensive review of pathology, molecular features, and differential diagnosis. Journal of Pathology and Translational Medicine. 2026;60(5):502-515. doi:10.4132/jptm.2026.08.01

BibTeX
@article{Danielson2026,
  author = {Danielson, David and Lagerstrom, Ian T and Rogers, Max and Simon, Kyle and Aguilera, Nadine S and Auerbach, Aaron},
  title = {T-lymphoblastic leukemia/lymphoma: a comprehensive review of pathology, molecular features, and differential diagnosis},
  journal = {Journal of Pathology and Translational Medicine},
  year = {2026},
  volume = {60},
  number = {5},
  pages = {502--515},
  doi = {10.4132/jptm.2026.08.01}
}
Kostenlos starten →